Cryoport, Inc. CYRX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy ("CGT") market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies. Our solutions help our customers ensure the safe, compliant storage, handling, and delivery of high value, temperature sensitive biological materials, including cell and gene therapies and immunotherapies.

We place particular emphasis on the CGT market, our fastest growing market, by delivering highly specialized, end-to-end supply chain solutions that support cell and gene therapy programs from preclinical research, through clinical trials, and ultimately to the global commercialization of approved therapies. As of December 31, 2025, Cryoport supported 760 clinical trials, and 20 commercially approved cell and gene therapies.

Last close 17.98 2026-10-23
Market cap $910.7M 2026-06-30 share count
52-week range 7.61 - 18.73

Valuation FY2025 figures against the last close

P/S5.2x
P/E12.8x
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS1.40

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $176.2M$156.8M$168.7M$237.3M$222.6M$78.7M$33.9M$19.6M$12.0M$7.7M
Cost of revenue $93.1M$87.1M$93.3M$133.4M$126.0M$42.4M$16.6M$9.4M$6.0M$4.6M
Gross profit $83.1M$69.7M$75.3M$103.9M$96.6M$36.3M$17.4M$10.2M$6.0M$3.1M
R&D $17.0M$17.7M$18.0M$15.7M$16.8M$9.5M$3.7M$1.8M$1.2M$598.1K
SG&A $102.8M$109.8M$108.3M$120.1M$97.6M$56.9M$31.3M$9.8M$7.4M$6.4M
Total operating expenses $119.9M$191.3M$175.9M$135.8M$114.4M$66.3M$35.0M$18.9M$13.9M$11.9M
Operating income -$36.8M-$121.7M-$100.5M-$31.9M-$17.8M-$30.0M-$17.7M-$8.6M-$7.9M-$8.8M
Interest expense $2.4M$4.0M$5.6M$6.1M$4.7M$2.6M$1.4M$69.3K$15.7K$139.4K
Pre-tax income -$32.2M-$104.3M-$84.2M-$35.1M-$273.8M-$32.7M-$18.3M-$9.5M-$7.9M-$13.1M
Income tax $1.8M$359.0K$345.0K$2.2M$1.7M$45.0K$62.0K$20.0K$5.1K$5.7K
Net income $78.3M-$114.8M-$99.6M-$37.3M-$275.5M-$32.7M-$18.3M-$9.6M-$7.9M-$13.1M
EPS, basic 1.40-2.49-2.21-0.93-6.18-1.94-0.55———
EPS, diluted 1.40-2.49-2.21-0.93-6.18-1.94-0.55-0.34-0.34-0.93
Shares, diluted (wtd. avg.) 50.1M49.3M48.7M49.0M45.9M38.6M33.4M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $250.5M$34.1M$35.2M$29.2M$139.1M$36.9M$47.2M$37.3M$15.0M$4.5M
Short-term investments $160.7M$216.5M$410.4M$486.7M$489.7M$56.4M$47.1M$9.9M$0—
Receivables $33.4M$25.3M$42.1M$43.9M$39.4M$31.4M$7.1M$3.5M$1.6M$1.2M
Inventory $23.2M$21.5M$26.2M$27.7M$16.5M$10.5M$474.0K$220.5K$114.8K$89.5K
Total current assets $476.2M$341.6M$535.1M$604.2M$693.5M$147.2M$103.0M$51.8M$17.3M$6.1M
Property, plant and equipment $85.4M$80.0M$84.9M$63.6M$49.0M$30.0M$11.8M$4.4M$2.5M$1.6M
Goodwill $22.4M$20.6M$76.4M$151.1M$147.0M$145.3M$11.0M$0——
Other intangibles $138.1M$147.9M$194.4M$191.0M$201.4M$213.9M$5.2M$137.2K$90.6K$5.0K
Total assets $765.0M$703.5M$957.7M$1.04B$1.11B$552.4M$135.9M$56.6M$20.3M$8.1M
Accounts payable $15.3M$15.9M$27.0M$28.0M$28.6M$24.8M$2.5M$1.7M$1.2M$1.2M
Total current liabilities $219.0M$64.6M$45.6M$40.9M$42.6M$35.0M$5.5M$3.1M$2.2M$2.2M
Total liabilities $262.4M$301.6M$468.7M$482.9M$471.1M$169.7M$9.6M$18.1M$2.4M$2.4M
Retained earnings -$688.9M-$757.2M-$642.4M-$542.8M-$467.5M-$192.0M-$159.3M-$141.0M-$131.4M-$123.5M
Total equity $502.6M$401.9M$489.0M$555.8M$641.8M$382.7M$126.3M$38.5M$17.9M$5.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$8.6M-$16.3M-$757.0K-$1.9M$8.1M-$14.9M-$1.3M-$3.4M-$3.6M-$5.7M
Depreciation and amortisation $27.7M$30.8M$27.5M$22.8M$20.2M$9.9M$2.4M$857.9K$664.8K$374.2K
Stock-based compensation $10.1M$16.6M$19.8M$20.1M$15.3M$8.9M$16.5M$5.5M$3.5M$3.1M
Capital expenditure $16.4M$17.3M$38.8M$22.1M$23.9M$8.9M$5.3M$2.9M$1.7M$1.1M
Investing cash flow $250.3M$176.8M$36.0M-$59.7M-$469.3M-$382.3M-$62.9M-$12.9M-$1.8M-$1.1M
Financing cash flow -$21.1M-$161.5M-$23.8M-$39.2M$564.3M$385.6M$74.2M$38.5M$15.9M$6.1M
Buybacks $10.0M——$38.0M$0$0————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016129.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -200M 0 200M 400M Revenue, FY2016: 7.7M Gross profit, FY2016: 3.1M Net income, FY2016: -13.1M Revenue, FY2017: 12M Gross profit, FY2017: 6M Net income, FY2017: -7.9M Revenue, FY2018: 19.6M Gross profit, FY2018: 10.2M Net income, FY2018: -9.6M Revenue, FY2019: 33.9M Gross profit, FY2019: 17.4M Net income, FY2019: -18.3M Revenue, FY2020: 78.7M Gross profit, FY2020: 36.3M Net income, FY2020: -32.7M Revenue, FY2021: 222.6M Gross profit, FY2021: 96.6M Net income, FY2021: -275.5M Revenue, FY2022: 237.3M Gross profit, FY2022: 103.9M Net income, FY2022: -37.3M Revenue, FY2023: 168.7M Gross profit, FY2023: 75.3M Net income, FY2023: -99.6M Revenue, FY2024: 156.8M Gross profit, FY2024: 69.7M Net income, FY2024: -114.8M Revenue, FY2025: 176.2M Gross profit, FY2025: 83.1M Net income, FY2025: 78.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $7.7M $12.0M $19.6M $33.9M $78.7M $222.6M $237.3M $168.7M $156.8M $176.2M
Gross profit $3.1M $6.0M $10.2M $17.4M $36.3M $96.6M $103.9M $75.3M $69.7M $83.1M
Net income -$13.1M -$7.9M -$9.6M -$18.3M -$32.7M -$275.5M -$37.3M -$99.6M -$114.8M $78.3M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Shareholder vote Item 5.07
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%